Sun Pharma Receives US FDA Approval for ILUMYA in Psoriatic Arthritis

Sun Pharmaceutical Industries received US FDA approval for ILUMYA (tildrakizumab-asmn) to treat psoriatic arthritis, expanding the drug’s use beyond existing dermatological conditions. The approval strengthens the company’s US specialty portfolio; commercial rollout details and eligible patient populations were not disclosed. The announcement provided no financial figures or stock-market impact.